Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q96S79

UPID:
RSLAB_HUMAN

ALTERNATIVE NAMES:
Ras-like protein VTS58635; Ras-related protein 17

ALTERNATIVE UPACC:
Q96S79; B3KV31

BACKGROUND:
The Ras-like protein family member 10B, with alternative names Ras-like protein VTS58635 and Ras-related protein 17, is key in cardiovascular health. It aids in the release of atrial natriuretic peptide from cardiomyocytes, crucial for arterial pressure regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ras-like protein family member 10B offers promising avenues for drug discovery, particularly for cardiovascular conditions. Its critical role in arterial pressure regulation positions it as an attractive target for developing novel therapeutics.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.